Petersen Kitt Falk, Oral Elif Arioglu, Dufour Sylvie, Befroy Douglas, Ariyan Charlotte, Yu Chunli, Cline Gary W, DePaoli Alex M, Taylor Simeon I, Gorden Phillip, Shulman Gerald I
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA.
J Clin Invest. 2002 May;109(10):1345-50. doi: 10.1172/JCI15001.
Lipodystrophy is a rare disorder that is characterized by selective loss of subcutaneous and visceral fat and is associated with hypertriglyceridemia, hepatomegaly, and disordered glucose metabolism. It has recently been shown that chronic leptin treatment ameliorates these abnormalities. Here we show that chronic leptin treatment improves insulin-stimulated hepatic and peripheral glucose metabolism in severely insulin-resistant lipodystrophic patients. This improvement in insulin action was associated with a marked reduction in hepatic and muscle triglyceride content. These data suggest that leptin may represent an important new therapy to reverse the severe hepatic and muscle insulin resistance and associated hepatic steatosis in patients with lipodystrophy.
脂肪营养不良是一种罕见的疾病，其特征是皮下和内脏脂肪选择性丢失，并伴有高甘油三酯血症、肝肿大和糖代谢紊乱。最近的研究表明，长期使用瘦素治疗可改善这些异常情况。在此我们表明，长期使用瘦素治疗可改善严重胰岛素抵抗的脂肪营养不良患者胰岛素刺激的肝脏和外周葡萄糖代谢。胰岛素作用的这种改善与肝脏和肌肉甘油三酯含量的显著降低有关。这些数据表明，瘦素可能是一种重要的新疗法，可逆转脂肪营养不良患者严重的肝脏和肌肉胰岛素抵抗以及相关的肝脂肪变性。
